Physician profile
Arjun D Iyengar
NPI 1053603340
$295,924.31
in general payments reported to CMS, 2019-2025
48 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $250 · 2021: $340 · 2022: $200K · 2023: $93K · 2024: $435 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $93K · Food and Beverage: $2,047 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $92,500.00 |
| Food and Beverage | $2,047.03 |
| Education | $299.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene (Suzhou) Co., Ltd. | $200,000.00 | 2022 | |
| Beigene, Ltd. | $92,500.00 | 2023 | |
| Janssen Biotech, INC. | $588.35 | 2019-2025 | Darzalex, Talvey, Erleada |
| Merck Sharp & Dohme LLC | $312.94 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $298.29 | 2019-2025 | Opdivo, Reblozyl |
| Exelixis INC. | $227.48 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $203.09 | 2019-2025 | |
| Lilly USA, LLC | $170.55 | 2019-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $151.08 | 2019-2025 | |
| Amgen INC. | $144.44 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $110.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $104.85 | 2019-2025 | |
| Celgene Corporation | $99.27 | 2022-2024 | Reblozyl |
| Daiichi Sankyo INC. | $79.98 | 2020-2025 | Enhertu |
| Beigene USA, INC. | $65.88 | 2023 | Brukinsa |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Iyengar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.